[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 67 of about 67
59. von Roon AC, Tekkis PP, Clark SK, Heriot AG, Lovegrove RE, Truvolo S, Nicholls RJ, Phillips RK: The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis. Dis Colon Rectum; 2007 Jul;50(7):952-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes were major complications, pouch function, and neoplastic transformation in the anal transitional zone.
  • The incidence of polyps at the anal transitional zone was lower with handsewn than with stapled anastomosis (19 vs. 38 percent; P=0.047).
  • Handsewn ileoanal anastomosis with mucosectomy seems to reduce the incidence of subsequent neoplasia in the anal transitional zone but does not eliminate the risk of cancer.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Incidence. Length of Stay. Male. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome


60. Saranovic Dj, Krivokapic Z, Masulovic D, Djuric A, Ivanovic A, Dobriserevic B, Markovic Z, Barisic G: Endoanal ultrasonography in establishing the diagnosis of fecal incontinence. Acta Chir Iugosl; 2007;54(3):159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoanal ultrasonography in establishing the diagnosis of fecal incontinence.
  • Local staging of rectal and anal tumor and perianal neoplasm by conventional and sibgle slice CT or by barium enema study is not so valuable.
  • During last decade, endoscopic ultrasound and magnetic resonance imaging have been recognised as methods of choice in establishing diagnosis of rectal, perirectal, anal and perianal diseases.
  • [MeSH-minor] Anal Canal / ultrasonography. Female. Humans

  • Genetic Alliance. consumer health - Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988050.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


61. Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I: Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report. Acta Med Okayama; 2008 Dec;62(6):421-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
  • Anorectal melanoma is a rare malignant tumor with a poor prognosis.
  • An 85-year-old man was referred to our hospital for further examination and treatment of an anal tumor 2 cm in size.
  • Endoscopic ultrasonography revealed that the depth of tumor invasion was confined to the submucosal layer.
  • Endoscopic mucosal resection was performed, and the tumor was diagnosed as a malignant melanoma.
  • The patient was followed without any additional treatment, which was per his wishes.
  • If the depth of tumor invasion is shallow, endoscopic mucosal resection is a useful option among other therapeutic modalities.
  • [MeSH-major] Anal Canal / surgery. Endoscopy / methods. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122689.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Allal AS, Br√ľndler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis; 2005 Mar;20(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
  • BACKGROUND: Histologically, tumors of the anal region are either keratinizing (K) or non-keratinizing (NK) squamous cell carcinomas (SCCA).
  • METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with anal canal cancers.
  • Expression of p53 and Bcl-2 was considered positive when >5% of tumor cells were stained.
  • Tumor histology was correlated with protein expression as well as with other clinical variables.
  • The proportion of Bcl-2 positive tumors was statistically higher in NK carcinomas (51.5 vs. 23.5%, p=0.009).
  • In addition, women were more likely than men to present with NK carcinomas (71 vs. 45%, p=0.03) as well as with Bcl-2 positive tumors (47 vs. 29%, p=0.05).
  • The more distal the tumor is (anal margin), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
  • By contrast, there was no correlation between p53 and tumor histology (p=0.83).
  • In addition, significant differences were observed in the distribution of these two histological subtypes according to gender and tumor sublocation.
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma, Squamous Cell / metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biopsy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Factors. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):210-4 [9683295.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):223-30 [11451553.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):214-9 [12562647.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 15688099.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Fagan SP, Bellows CF 3rd, Albo D, Rodriquez-Barradas M, Feanny M, Awad SS, Berger DH: Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. Am J Surg; 2005 Nov;190(5):732-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma.
  • BACKGROUND: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV).
  • We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma.
  • METHODS: HIV-positive patients diagnosed with anal neoplasms were reviewed.
  • RESULTS: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2).
  • CONCLUSIONS: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease.
  • As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma / etiology. HIV. HIV Infections / complications. Immune Tolerance / physiology
  • [MeSH-minor] Adult. Biopsy. CD4 Lymphocyte Count. Follow-Up Studies. HIV Antibodies / analysis. Humans. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Retrospective Studies. Risk Factors


6
Advertisement
4. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • RESULTS: Of the 90 cases, 82.5% showed tumor downsizing, varying from one-third to two-thirds or more of the original tumor mass.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • The distal margin was tumor free in these cases.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology


66. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis; 2010 Oct 15;202(8):1246-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer.
  • Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.
  • Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded.
  • The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J STD AIDS. 2009 Sep;20(9):595-600 [19710329.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1949-57 [19493565.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15 [12522048.001]
  • [Cites] BMC Infect Dis. 2003 Apr 30;3:6 [12723991.001]
  • [Cites] Am J Obstet Gynecol. 1984 Aug 15;149(8):815-23 [6205589.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1345-55 [1318640.001]
  • [Cites] J Clin Microbiol. 1992 Oct;30(10):2539-43 [1328278.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):625-31 [9291307.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69 [16085914.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1045-8 [16142673.001]
  • [Cites] Vaccine. 2006 Jan 16;24(3):272-9 [16139398.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • (PMID = 20812850.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00513526
  • [Grant] United States / NCI NIH HHS / CA / U01CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCRR NIH HHS / RR / UL1 RR024996-01; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCRR NIH HHS / RR / M01 RR000865-26; United States / NCRR NIH HHS / RR / UL1RR024996; United States / NIAID NIH HHS / AI / K23 AI055038; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NCI NIH HHS / CA / U01 CA121947-01; United States / NIAID NIH HHS / AI / K23 AI 55038; United States / NIAID NIH HHS / AI / K23 AI055038-01; United States / NCI NIH HHS / CA / CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024131-01; United States / NCRR NIH HHS / RR / M01-RR00865; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIAID NIH HHS / AI / AI055038-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS285476; NLM/ PMC3118428
  •  go-up   go-down


67. Elgin Y, Demirkasimoglu T, Kucukplakci B, Altundag MB, Altundag K, Misirlioglu C, Sanri E, Erkal H, Ugur I, Kara P, Ozgen A, Ozdamar N: Anal tumor diagnosed after the recovery of Fournier gangrene. Dig Dis Sci; 2006 May;51(5):889-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal tumor diagnosed after the recovery of Fournier gangrene.
  • [MeSH-major] Adenocarcinoma / complications. Anus Neoplasms / complications. Fournier Gangrene / etiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Jun;87(6):718-28 [10848848.001]
  • [Cites] Surg Clin North Am. 1994 Dec;74(6):1339-52 [7985069.001]
  • [Cites] Hinyokika Kiyo. 2000 Oct;46(10):735-7 [11215202.001]
  • [Cites] Am J Gastroenterol. 1998 Apr;93(4):657-8 [9576470.001]
  • [Cites] BMC Cancer. 2004 Apr 27;4:16 [15113443.001]
  • [Cites] Pol Merkur Lekarski. 2004 Jul;17(97):62-3 [15559615.001]
  • (PMID = 16642420.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement